Sodium hydride → 1-methyl-4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione
Reaction equation
[CH3:1][N:2]1[C:8]2[CH:9]=[CH:10][C:11]([C:13]3[CH:18]=[CH:17][C:16]([O:19][C:20]([F:23])([F:22])[F:21])=[CH:15][CH:14]=3)=[CH:12][C:7]=2[C:6](=[O:24])[NH:5][CH2:4][C:3]1=[O:25].[H-].[Na+].Cl.Cl[CH2:30][C:31]1[N:36]=[CH:35][CH:34]=[CH:33][N:32]=1>CN(C=O)C>[CH3:1][N:2]1[C:8]2[CH:9]=[CH:10][C:11]([C:13]3[CH:14]=[CH:15][C:16]([O:19][C:20]([F:23])([F:21])[F:22])=[CH:17][CH:18]=3)=[CH:12][C:7]=2[C:6](=[O:24])[N:5]([CH2:30][C:31]2[N:36]=[CH:35][CH:34]=[CH:33][N:32]=2)[CH2:4][C:3]1=[O:25]Participants
5
Reactant 3
Product 1
Reagents, catalysts & solvents 1
Procedure
1-Methyl-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione (22.9 mg, 0.065 mmol) and NaH (15.6 mg, 0.650 mmol, 10.0 equiv.) were placed in a 0.5-2 mL Smith process vial. To the vial was added DMF (0.5 mL) followed by 2-(chloromethyl)pyrimidine hydrochloride (53.9 mg, 0.327 mmol, 5 equiv.) was added at room temperature. After stirring for 50 min, reaction was quenched with AcOH. Resulting mixture was filtered and purified via preparative reverse phase HPLC to give the title compound (2.2 mg) as a clear yellow film.
Workup
- additionwas added at room temperature
- customreaction
- customwas quenched with AcOH
- customResulting mixture
- filtrationwas filtered
- custompurified via preparative reverse phase HPLC
Sources & evidence
- ORD record
- ord-d7a3c878047e43d6a2c7819cf73dbc32
- Source dataset
- uspto-grants-2015_11
- Patent number
- US09193694B2
Reaction notes
Loading…